One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage All Access membership.
Explore Editage All Access
Open Accesshttps://doi.org/10.1182/blood-2021-147758
Copy DOI Journal: Blood |  Publication Date: Nov 5, 2021 |
 Citations: 1 |
Affiliation: Moffitt Cancer Center, Fred Hutch Cancer Center, University of Washington, Emory University, Nektar Therapeutics (United States), The University of Texas MD Anderson Cancer Center, New York Medical College, Virginia Cancer Specialists, University of Michigan–Ann Arbor, Rush University Medical Center, Memorial Sloan Kettering Cancer Center, Duke University, City of Hope, University of California, San FranciscoSafety, Tolerability, PK/PD and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in Patients with Relapsed/Refractory Hematologic Malignancies
Sign-in/Register to access full text options 
Free) Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
